Invitrogen Launches New Microarray System to Simplify Immunogenetic Testing

Prodigy System Advances Process for HLA in Stem Cell and Solid Organ Transplant Research

Invitrogen, part of Life Technologies Corporation (NASDAQ:LIFE), today announced the commercial availability of a state-of-the-art, automated, research-use microarray system designed to simplify immunogenetic testing, including human leukocyte antigen (HLA) research. The new Prodigy™ system is an advanced DNA and protein analysis tool that simplifies and accelerates histocompatibility research, vaccine and drug development, and disease association studies.

The Prodigy system is the first high-throughput, next-generation, sequence-specific oligonucleotide probe system that streamlines sample workflow for hybridizing, detecting and analyzing HLA markers in large-volume variation analysis and genotyping research studies. HLA markers are cell-surface proteins that play a key regulation role in the human immune system, functioning as an alert mechanism when the body has been invaded by foreign proteins or molecules, such as bacteria, parasites and viruses. The Prodigy system represents a significant advancement in technologies for this type of research, providing scientists with a simplified workflow for cleaner, consistent and reproducible results, while reducing hands-on interaction with the system, resulting in decreased variability, errors and the need for repeat testing.

The Prodigy system features several technological advancements over other systems in the market. It has 5-times the density capacity of current bead-based assays and is enabled by push-button, walk-away automation, enabling researchers to spend valuable time reviewing data or preparing more samples. Prodigy is inherently scalable to include multiplexing capability for more than 500 analytes, while providing high resolution and unmatched efficiency and reliability.

It is also capable of industry-leading throughput that equates to approximately 290 genotypes in 9 hours, and includes integrated software that simplifies data analysis and interpretation. And, with capacity for more than 500 analytes, the Prodigy system is uniquely scalable to accommodate new alleles to be identified in the future, enabling it to be easily incorporated into existing infrastructure. This provides researchers with a future-proof technology that will enable them to not only expand, but to also advance their research over a significant period of time.

Jim Janicki , VP & General Manager of Life Technologies’ Transplantation Diagnostics Business

"The development of the Prodigy microarray system is the latest development in Invitrogen’s strategy to make its best-in-class genomic and proteomic technologies available within the HLA research field. This powerful system provides an end-to-end solution that will help researchers advance their immunogenetic studies.”

Resources

• Prodigy System
• Prodigy System Brochure

For more information, please visit: www.invitrogen.com and www.appliedbiosystems.com .

About Life Technologies

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of more than $3 billion in 2008, employs approximately 9,500 people, has a presence in more than 100 countries, and possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc. For more information on how we are making a difference please visit our website: www.lifetechnologies.com .